SCIENCE NEWS Scientists Show TAp63 Suppresses Cancer Metastasis Long overshadowed by p53, its famous tumor-suppressing sibling, the p63 gene does the tougher, important job of stifling the spread of cancer to other organs. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in Nature]
|
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) LABORATORY RESEARCH A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-Modulation of the Estrogen Receptor in HER2-Positive Breast Cancers The results reveal a mechanism of estrogen receptor regulation mediated by human epidermal growth factor receptor 2, which suggests a new strategy to improve responses to endocrine therapy in breast cancer. [Cancer Res] mTOR Complex Component Rictor Interacts with PKCZeta and Regulates Cancer Cell Metastasis Here, researchers report that the rapamycin-insensitive mTORC2 component protein Rictor is a critical mediator of metastasis in breast cancer cells. [ Cancer Res] Down-Regulation of the Oncogene Cyclin D1 Increases Migratory Capacity in Breast Cancer and Is Linked to Unfavorable Prognostic Features The oncogene cyclin D1 is highly expressed in many breast cancers and, despite its proliferation-activating properties, it has been linked to a less malignant phenotype. To clarify this observation, researchers focused on two key components of malignant behavior, migration and proliferation, and observed that quiescent G0/G1 cells display an increased migratory capacity compared to cycling cells. [Am J Pathol] Adipocyte Derived Paracrine Mediators of Mammary Ductal Morphogenesis Controlled by Retinoic Acid Receptors Researchers generated a transgenic-mouse model expressing a dominant negative-RARalpha, (RARalphaG303E) under adipocytes-specific promoter to explore the paracrine role of adipocyte retinoic acid receptors (RARs) in mammary morphogenesis. [Dev Biol] RB-Pathway Disruption in Breast Cancer: Differential Association with Disease Subtypes, Disease-Specific Prognosis and Therapeutic Response Researchers investigated RB pathway deregulation in the context of both ER-positive and ER-negative disease using combined microarray datasets encompassing over 900 breast cancer patient samples. [Cell Cycle] Expression of ctBP Family Protein Isoforms in Breast Cancer and Their Role in Chemoresistance The studies support recent evidence that CtBP family proteins represent potential targets for therapeutic strategies for the treatment of cancer in general, and breast cancer in particular. [Biol Cell] Spontaneously Immortalised Bovine Mammary Epithelial Cells Exhibit a Distinct Gene Expression Pattern from the Breast Cancer Cells Here, researchers report the establishment of a spontaneously immortalised bovine mammary epithelial cell line (BME65Cs) and the changes in gene expression associated with BME65Cs cells. [BMC Cell Biol] CLINICAL RESEARCH Long-Term Survival Among Patients With Hodgkin’s Lymphoma Who Developed Breast Cancer: A Population-Based Study Women with Hodgkin’s lymphoma may survive a subsequent diagnosis of breast cancer, only to experience significant excesses of death from other primary cancers and cardiac disease. [J Clin Oncol] Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab The purpose of this study was to determine the recommended dose of everolimus, a mammalian target of rapamycin inhibitor, combined with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor 2 (HER2) -overexpressing metastatic breast cancer pretreated with trastuzumab. [J Clin Oncol] Increased NOS2 Predicts Poor Survival in Estrogen Receptor-Negative Breast Cancer Patients To investigate whether nitric oxide synthase (NOS2) levels influence survival of breast cancer patients, researchers examined NOS2 expression and its association with tumor markers and survival in 248 breast tumors. [J Clin Invest] Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects This is the first study demonstrating that single oral doses of endoxifen are safe and well tolerated and have sufficient bioavailability to reach systemically effective levels in human subjects. [Clin Pharmacol Ther] A Protein Microarray Signature of Autoantibody Biomarkers for the Early Detection of Breast Cancer Cancer patients spontaneously generate autoantibodies (AAb) to tumor-derived proteins. To detect AAb, researchers have probed novel high-density custom protein microarrays (NAPPA) expressing 4,988 candidate tumor antigens with sera from patients with early stage breast cancer, and bound IgG was measured. [J Proteome Res]
|
|
INDUSTRY NEWS Unique Database of Cancer – Designed to Personalize Treatment – Is Launched Georgetown Lombardi Comprehensive Cancer Center announces the launch of the Georgetown Database of Cancer or G-DOC. Under development for two years, G-DOC is a repository for biological information that is normally only available in scattered information libraries and tissue banks, if at all. [Georgetown University Medical Center Press Release] Myriad and Abbott Enter Into Cooperative Agreement Myriad Genetics, Inc. announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study of a novel drug candidate for the treatment of metastatic breast cancer. [Myriad Genetics, Inc. Press Release] BioSante Pharmaceuticals Reports Positive LibiGel(R) Data Monitoring Committee Recommendation BioSante Pharmaceuticals, Inc. announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). [BioSante Pharmaceuticals, Inc. Press Release]
|
|
POLICY NEWS NIH Recovery Act Awards Enable Crucial Health Research Technologies Thanks to the Recovery Act, more health scientists now will have access to state-of-the-art devices, the National Institutes of Health announced. Through its National Center for Research Resources, NIH has awarded $300 million in shared instrumentation grants. [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26362) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26363) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26317) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26497) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26499) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26028) [National Institutes of Health, United States] National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-26702) [National Institutes of Health, United States] National Cancer Institute; Notice of Closed Meetings (FR Doc. 2010-26706) [National Institutes of Health, United States] National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-26390) [National Institutes of Health, United States] Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-26036) [National Institutes of Health, United States]
|
|
EVENTS (Listed by Date) Queen Mary University of London: 5th UK Cancer Stem Cell Symposium November 2, 2010 London, United Kingdom National Cancer Research Institute (NCRI) Conference 2010 November 7-10, 2010 Liverpool, United Kingdom 9th Annual American Association for Cancer Research (AACR) International Conference: Frontiers in Cancer Prevention Research November 7-10, 2010 Philadelphia, United States NEW Third Annual Research Experience of Stem Cells in European Society (RESCUES) Conference November 8-9, 2010 Oxford, United Kingdom The 16th International Conference of the International Society of Differentiation: From Stem Cells to Organisms November 15-18, 2010 Nara, Japan 22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics November 16-19, 2010 Berlin, Germany 5th Annual Stem Cell Meeting on the Mesa December 7, 2010 La Jolla, United States American Association for Cancer Research (AACR) 33rd Annual San Antonio Breast Cancer Symposium December 8-12, 2010 San Antonio, United States Keystone Symposia: Epithelial Plasticity and Epithelial to Mesenchymal Transition January 21-26, 2011 Vancouver, Canada 5th Annual Stem Cells and Regenerative Medicine World Congress January 24-25, 2011 San Diego, United States Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment February 23-25, 2011 San Francisco, United States American Association for Cancer Research (AACR) Targeting PI3K/mTOR Signaling in Cancer February 24-27, 2011 San Francisco, United States American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer March 3-6, 2011 Vancouver, Canada 28th Annual Miami Breast Cancer Conference March 9-12, 2011 Miami, United States MENA Oncology Conference March 11-12, 2011 Cairo, Egypt NEW United Kingdom National Stem Cell Network 2011 Annual Scientific Conference March 30-April 1, 2011 York, United Kingdom American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 April 2-6, 2011 Orlando, United States International Society for Stem Cell Research (ISSCR) 9th Annual Meeting June 15-18, 2011 Toronto, Canada 4th Annual Advances in Biodetection & Biosensors Conference and Exhibition June 30-July 1, 2011 Hamburg, Germany Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies) Lab Technologist – Tissue Culture (STEMCELL Technologies) Product Manager – Pluripotent Stem Cells (STEMCELL Technologies) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost. Visit here to post your career opportunities.
Have we missed an important article or publication in Mammary Cell News? Click here to submit! |
| |
|